Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Autoplex T (anti-inhibitor coagulant complex)
- tranexamic acid
Interactions between your drugs
anti-inhibitor coagulant complex tranexamic acid
Applies to: Autoplex T (anti-inhibitor coagulant complex), tranexamic acid
GENERALLY AVOID: Due to additive or synergistic pharmacodynamic effects, the risk of thrombosis may be increased when antifibrinolytic agents (e.g., aminocaproic acid, aprotinin, tranexamic acid) are coadministered with other hemostatic agents such as factor VIII inhibitor bypassing fraction, factor IX complex, prothrombin complex, or direct oral anticoagulant reversal agents.
MANAGEMENT: Concomitant administration of antifibrinolytic agents with other hemostatic agents should generally be avoided. Consult the manufacturer's product labeling for recommended dosing intervals between products.
References (4)
- (2001) "Product Information. Amicar (aminocaproic acid)." Immunex Corporation
- (2001) "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn
- (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc
- (2023) "Product Information. Tranexamic Acid (tranexamic acid)." Armas Pharmaceuticals, Inc.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lysteda
Lysteda (tranexamic acid) is used to treat heavy menstrual bleeding. Includes Lysteda side effects ...
Hemlibra
Hemlibra is a monoclonal antibody that functions in place of a natural blood-clotting factor that ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
DDAVP
DDAVP is used for diabetes insipidus, hemophilia a, primary nocturnal enuresis, von Willebrand Disease
Qfitlia
Qfitlia is used for hemophilia a, hemophilia a with inhibitors, hemophilia b, hemophilia b with ...
Altuviiio
Altuviiio is a once-weekly recombinant fact VIII replacement therapy used by hemophilia A patients ...
Cyklokapron
Cyklokapron is used for bleeding disorder, factor ix deficiency, hemophilia a
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.